All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
Very recently, eprenetapopt (APR-246), a small molecule that reactivates mutant and inactivated p53 protein, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of TP53-mutated acute myeloid leukemia (AML).1
TP53-mutated AML is associated with resistance to treatment and poor prognosis. Eprenetapopt restores wild-type p53 conformation and function, inducing apoptosis in cancer cells. In December 2020, eprenetapopt received FDA fast track designation for AML, as well as FDA breakthrough therapy designation, orphan drug designation, and fast track designation for the treatment of myelodysplastic syndromes (MDS). The agent also holds an orphan drug designation from the European Medicines Agency (EMA) for MDS, AML, and ovarian cancer.
The phase II Groupe Francophone des Myélodysplasies (GFM)-APR trial (NCT03931291) is currently investigating eprenetapopt combined with azacitidine for patients with AML or MDS harboring TP53 mutation. The study results, which can be found here, suggest encouraging safety and efficacy in this patient population.
Expansion of trial of eprenetapopt in combination with venetoclax and azacitidine in patients with TP53-mutated AML
On July 16, 2020, it was announced that the phase I trial (NCT04214860), evaluating eprenetapopt in combination with venetoclax and...
Eprenetapopt receives FDA Fast Track designation for the treatment of AML
On November 30, 2020, it was announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to eprenetapopt/APR-246 for the treatment of patients...
Subscribe to get the best content related to AML delivered to your inbox